News

Covi-TRaC: arming our immune cells against SARS-COV2

September 11, 2020

Prolific for researchers, the confinement period has allowed the French Establishment of Blood’s (EFS) teams to give birth to and mature many ideas from pre-existing studies. About fifteen projects were submitted to the national EFS as part of the anti-covid research program. A team from Besançon was thus allocated dedicated seed funding for their project considered as a priority - 3 in total were selected.

Contrary to calls for proposals, particularly European ones, launched in the midst of a crisis and calling for immediate applications (production of masks, hydroalcoholic solutions, etc.), this work carried out within the EFS Bourgogne-Franche-Comté (Besançon) aims to identify immune cells that recognize the virus in order to be able to provide medical applications in the medium and long term.

Marina Deschamps and Christophe Ferrand, both researchers at the Right Institute (UMR 1098) and the EFS, have used their twenty years of experience in the field of antitumor cell immunotherapy and CAR-T cells to imagine a process adapted to the treatment of COVID-19.

Their Covi-TRaC project consists of isolating T-lymphocytes so that they can be reprogrammed, armed and used against cells infected with SARS-COV2. The research is being conducted in support of the Coviplasm trial and other EFS teams.

How does it work?

Every person is born with a pool of basic immune cells that we educate throughout our lives: some people are therefore armed to react to the virus and develop adapted "T receptors".

The Coviplasm project collects plasma from these convalescent patients to study it for therapeutic purposes. Using these samples, Covi-TRaC isolates the T-lymphocytes present in the blood to identify the genes that have recognized the disease, using molecular biology technologies. These genes are then transferred to "naïve" T-cells to gain recognition of the disease and kill the infected cell.

"This is a technique we've been using for a long time in the field of CAR-T cells," explain the two researchers, who almost obviously "adapted their research to a new target", this time viral rather than tumoural.

This process should yield good results, especially for immunocompromised patients, for whom a vaccine would not be applicable.

What are the results?

The research carried out within Covi-TRaC has a twofold interest: therapeutic but primarily scientific, since it provides a better understanding of the deregulation of the immune system caused by the virus.

Indeed, the application of this type of research up to the production of a treatment is very long. Marina Deschamps insists "we all necessarily want to be able to provide new options for patients, but we don't have miracle solutions". And yet, by helping to understand the disease and how it works, they are contributing to the knowledge that is shared worldwide.

News

Landau Partnership

September 22, 2021

VectorBuilder Inc., a global leader in vector design, optimization and GMP manufacturing, and Landau Biotechnology Co., a world leader in developing nonhuman primate (NHP) models for clinical research applications, have...

Learn more

Univercells Partnership

September 16, 2021

VectorBuilder – a global leader in vector design, optimization, and GMP manufacturing – has formed a worldwide strategic partnership with Univercells Technologies, a provider of novel biomanufacturing technologies for flexible...

Learn more

The MACSima™ Imaging Platform is the only complete solution for ultra high content imaging experiments.

September 13, 2021

Learn more

New automated process to simplify the manufacturing of gene-engineered hematopoietic stem cells with the CliniMACS Prodigy® HSC Engineering System

September 13, 2021

Learn more

MedXCell SA

August 25, 2021

MedXCell Science SA: MedXCell Science SA was co-founded in 2018 by the University Hospital of Montpellier (CHU of Montpellier) in France and the Swiss company MedXCell SA. It was the...

Learn more

Cryoport Systems now supporting 7 commercial therapies globally

July 27, 2021

Learn more

Polyplus-transfection initiates construction of Vectura, a new 4,000m2 facility

July 23, 2021

Learn more

Polyplus-transfection® launches FectoVIR®-AAV

July 23, 2021

Learn more

RD-Biotech: a new company from Besançon wins the « France Relance » call for projects

February 22, 2021

Following the unprecedented health crisis and its unprecedented economic impact, the Government has put in place numerous tools to support businesses.

Learn more